You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

17-093

Showing 1 - 25 of 3,505
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Iron Deficiency Anemia (IDA) Trial in Poland, Russian Federation (Ferric Carboxymaltose (FCM))

Completed
Has Results
  • Iron Deficiency Anemia (IDA)
  • Ferric Carboxymaltose (FCM)
  • Bydgoszcz, Poland
  • +9 more
Jul 21, 2022

Juvenile Idiopathic Arthritis Trial in Worldwide (Sarilumab)

Active, not recruiting
  • Juvenile Idiopathic Arthritis
  • Los Angeles, California
  • +34 more
May 10, 2022

Digestive System Disease Trial in Worldwide (Eziclen®/Izinova®, Klean-Prep®)

Completed
Has Results
  • Digestive System Disease
  • Praha, Czechia
  • +23 more
Mar 1, 2021

Generalized Myasthenia Gravis Trial in Worldwide (efgartigimod PH20 SC)

Active, not recruiting
  • Generalized Myasthenia Gravis
  • efgartigimod PH20 SC
  • Carlsbad, California
  • +46 more
Jul 5, 2022

Generalized Myasthenia Gravis Trial in Worldwide (efgartigimod PH20 SC, efgartigimod IV)

Completed
  • Generalized Myasthenia Gravis
  • efgartigimod PH20 SC
  • efgartigimod IV
  • Carlsbad, California
  • +46 more
Jan 31, 2022

Cytomegalovirus Retinitis, HIV Trial in United States (Foscarnet sodium)

Completed
  • Cytomegalovirus Retinitis
  • HIV Infections
  • Foscarnet sodium
  • Los Angeles, California
  • +10 more
Oct 26, 2021

Metastatic Breast Cancer Trial in New York (PU-H71, Nab-paclitaxel)

Completed
  • Metastatic Breast Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 17, 2021

Crohn Disease Trial in Worldwide (Ustekinumab)

Completed
Has Results
  • Crohn Disease
  • Antwerpen, Belgium
  • +106 more
Aug 6, 2021

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.1 GBq (30 mCi) of 177Lu-P17-087
  • 1.1 GBq (30 mCi) of 177Lu-P17-088
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 30, 2022

Primary Sjögren Syndrome Trial (68Ga-P16-093)

Not yet recruiting
  • Primary Sjögren Syndrome
  • (no location specified)
Sep 19, 2023

Partial Epilepsy Trial in Worldwide (800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo)

Completed
Has Results
  • Partial Epilepsy
  • 800 mg QD Eslicarbazepine acetate
  • +2 more
  • Mobile, Alabama
  • +161 more
Apr 29, 2021

Post-Dural Puncture Headache, Cesarean Section Complications Trial in Faisalabad (Traditional Physical Therapy, Muscle Energy

Recruiting
  • Post-Dural Puncture Headache
  • Cesarean Section Complications
  • Traditional Physical Therapy
  • Muscle Energy Technique
  • Faisalabad, Punjab, Pakistan
    Madinah Teaching Hospital
Apr 18, 2023

Myasthenia Gravis Trial in Worldwide (Nipocalimab, Placebo)

Recruiting
  • Myasthenia Gravis
  • Mobile, Alabama
  • +134 more
Aug 19, 2022

Allergic Rhinitis Trial in Lublin (Ismigen, Placebo)

Completed
  • Allergic Rhinitis
  • Lublin, Poland
    Department of Pulmonary Diseases and Children Rheumatology, Medi
Apr 2, 2022

Breast Cancer Trial in Beijing (Drug: 68Ga-P16-093)

Recruiting
  • Breast Cancer
  • Drug: 68Ga-P16-093
  • Beijing, China
    Peking Union Medical College Hospital
Nov 14, 2022

Glioma Trial in Beijing (68Ga-P16-093)

Recruiting
  • Glioma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 4, 2022

Prostate Cancer Trial in Beijing (68Ga-P16-093, 68Ga-PSMA-11)

Recruiting
  • Prostate Cancer
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 1, 2022

Allergic Rhinitis Due to Grass Pollen Trial in Lublin (Ismigen, Placebo)

Completed
  • Allergic Rhinitis Due to Grass Pollen
  • Lublin, Poland
    Department of Pulmonary Diseases and Children Rheumatology, Medi
Apr 2, 2022

Intraventricular Hemorrhage of Prematurity Trial in Orlando (Tortle Midliner)

Terminated
Has Results
  • Intraventricular Hemorrhage of Prematurity
  • Tortle Midliner
  • Orlando, Florida
    Orlando Health
May 11, 2022

COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus

Completed
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
  • Taizhou, Jiangsu, China
    Taixing City center for Disease Control and Prevention
Oct 28, 2022

Breast Cancer, Triple Negative Breast Tumors Trial in France (Nivolumab, Ipilimumab, Capecitabine)

Active, not recruiting
  • Breast Cancer
  • Triple Negative Breast Neoplasms
  • Angers, France
  • +16 more
Jul 21, 2022

Prostate Cancer Trial in Beijing (68Ga-PSMA-617, 68Ga-P16-093)

Recruiting
  • Prostate Cancer
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Aug 4, 2022

Obstructive Hypertrophic Cardiomyopathy

Completed
  • Microvascular Dysfunction
  • +2 more
    • Beijing, Beijing, China
      Fuwai Hospital, China National Center for Cardiovascular Disease
    Jan 11, 2023

    Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-P16-093, 18F-FDG)

    Recruiting
    • Clear Cell Renal Cell Carcinoma
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Jun 21, 2022

    Cervical Cancer Trial (Curcumin, Palliative radiotherapy)

    Not yet recruiting
    • Cervical Cancer
    • (no location specified)
    Jul 14, 2023